<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20220" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cystitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Li</surname>
            <given-names>Raymund</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Raymund Li declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20220.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Cystitis refers to infection of the lower urinary tract, or more specifically, the urinary bladder. It may be broadly categorized as either uncomplicated or complicated. Uncomplicated cystitis refers to lower urinary tract infection (UTI) in either men or non-pregnant women who are otherwise healthy. Acute cystitis is typically caused by a bacterial infection of the urinary bladder. Complicated cystitis, on the other hand, is associated with risk factors that increase the virulence of the infection or the potential of failing antibiotic therapy. Acute cystitis is typically caused by a bacterial infection of the urinary bladder. Women are particularly susceptible due to the proximity of the rectum to the urethral meatus as well as the relatively short urethral length in females. This activity reviews the evaluation and treatment of cystitis and describes the role of the interprofessional team in the care of patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the causes of cystitis.</p></list-item><list-item><p>Describe the presentation of cystitis.</p></list-item><list-item><p>Summarize the treatment of cystitis.</p></list-item><list-item><p>Explain modalities to improve care coordination among interprofessional team members to improve outcomes for patients affected by cystitis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20220&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20220">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20220.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Cystitis refers to infection of the lower urinary tract, or more specifically, the urinary bladder.<xref ref-type="bibr" rid="article-20220.r1">[1]</xref><xref ref-type="bibr" rid="article-20220.r2">[2]</xref>&#x000a0;It may be broadly categorized as either complicated or uncomplicated (simple). Uncomplicated cystitis refers to a lower urinary tract infection (UTI) in either men or non-pregnant women who are otherwise healthy. On the other hand, complicated cystitis is associated with risk factors that increase the likelihood and danger of the infection or the chances of failing antibiotic therapy.&#x000a0;</p>
      </sec>
      <sec id="article-20220.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Acute cystitis is typically caused by a bacterial infection of the urinary bladder. Women are particularly susceptible due to the close proximity of the rectum to the urethral meatus as well as the relatively short urethral length in females. Accounting for approximately 75% to 95% of cases,&#x000a0;<italic toggle="yes">Escherichia coli</italic>&#x000a0;is the most common etiologic agent in uncomplicated UTIs in women, followed by Klebsiella.<xref ref-type="bibr" rid="article-20220.r3">[3]</xref> Other common etiologic pathogens include species of the <italic toggle="yes">Enterobacteriaceae</italic> family, such as <italic toggle="yes">Proteus mirabilis,</italic>&#x000a0;and&#x000a0;other bacteria, such as <italic toggle="yes">Staphylococcus saprophyticus </italic>and<italic toggle="yes"> enterococcus. </italic>Other bacterial species very rarely cause UTIs and usually represent contamination when isolated from&#x000a0;the urine culture of an otherwise healthy person. These include bacteria such as Group B <italic toggle="yes">streptococci</italic>, <italic toggle="yes">Lactobacillus</italic>, and other coagulase-negative <italic toggle="yes">staphylococci&#x000a0;</italic>other than <italic toggle="yes">S. saprophyticus</italic><italic toggle="yes">.</italic><xref ref-type="bibr" rid="article-20220.r4">[4]</xref><xref ref-type="bibr" rid="article-20220.r5">[5]</xref><xref ref-type="bibr" rid="article-20220.r6">[6]</xref></p>
        <p><italic toggle="yes">Escherichia coli</italic>&#x000a0;is also the most common cause of complicated cystitis, but the spectrum of microbial pathogens that may cause a complicated UTI is much broader and includes organisms such as <italic toggle="yes">Enterobacter</italic>, <italic toggle="yes">Citrobacter</italic>, <italic toggle="yes">Serratia</italic>, <italic toggle="yes">Pseudomonas,</italic>
<italic toggle="yes">enterococci</italic>, <italic toggle="yes">staphylococci</italic>, and even fungi. The incidence of antimicrobial resistance in complicated infections is also significantly higher. Notable resistant organisms include the extended-spectrum beta-lactamase (ESBL) producing bacteria, as well as carbapenem-resistant and fluoroquinolone-resistant organisms, particularly<italic toggle="yes"> E. coli</italic>.<xref ref-type="bibr" rid="article-20220.r7">[7]</xref><xref ref-type="bibr" rid="article-20220.r8">[8]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-20220.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Approximately one-third of women will have had a UTI by age 24 and one-half by age 32. The incidence of UTI is 12% in women based on self-reported annual incidence. A university cohort study estimates the annual incidence of UTI at 0.5 to 0.7 UTIs per person-year in sexually active women. Factors that increase the risk for uncomplicated cystitis include sexual intercourse, spermicide use, new sex partner within the past year, previous UTI, strong family history of UTI in a first-degree female relative, and post-menopausal state. Acute cystitis is much more common than pyelonephritis, with an estimated ratio of 18 to 28 cystitis episodes for every episode of pyelonephritis.<xref ref-type="bibr" rid="article-20220.r9">[9]</xref></p>
        <p>Depending on the underlying condition, there is wide variation in the incidence of complicated UTIs. The estimated prevalence of asymptomatic bacteriuria in women with diabetes is 26% compared to 6% in non-diabetic females. Patients with diabetes are also at increased risk of developing both acute cystitis and pyelonephritis. UTIs are common in patients who had renal transplantation, with retrospective cohort studies showing an incidence between 47% and 75%.<xref ref-type="bibr" rid="article-20220.r10">[10]</xref></p>
        <p>The risk is highest in the first year post-transplantation. Approximately 2.3% of pregnant women develop a symptomatic UTI. Other risk factors for developing a complicated UTI include nephrolithiasis, immunocompromised status, the presence of foreign bodies such as a urinary catheter, urinary tract instrumentation, renal insufficiency, functional or anatomic abnormality of the urinary tract, urinary stents, strictures, and obstructive uropathy.<xref ref-type="bibr" rid="article-20220.r11">[11]</xref>&#x000a0;</p>
        <p>The incidence of simple cystitis in men is relatively low. It is estimated&#x000a0;to be fewer than 10 cases per year per 10,000 men under age 65.<xref ref-type="bibr" rid="article-20220.r12">[12]</xref>&#x000a0;Symptoms of a simple UTI in men are the same as in women; dysuria, urinary frequency, urgency, and suprapubic pain. Recurrent symptoms or reinfections after treatment, fever and pelvic or perineal pain suggest prostatitis. Fever, chills, flank pain, or any signs of a systemic illness suggest a complicated urinary tract infection.<xref ref-type="bibr" rid="article-20220.r11">[11]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-20220.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Cystitis usually develops due to the colonization of the periurethral mucosa by bacteria from the fecal or vaginal flora and the ascension of such pathogens to the urinary bladder. Uropathogens may have microbial virulence factors that allow them to escape host defenses and invade tissues in the urinary tract. UTIs in males are much less common due to the longer anatomic urethra, the drier periurethral environment, and the antibacterial defenses provided by the prostatic fluid. Traditionally, all UTIs in males were considered complicated. However, uncomplicated UTIs may occasionally occur, especially in males between 15 and 50, especially in those who are sexually active, are uncircumcised, or do anal intercourse, as long as they do not have any risk factors for complicated UTIs such as urologic abnormalities, bladder outlet obstruction, urolithiasis or recent urinary tract instrumentation.<xref ref-type="bibr" rid="article-20220.r13">[13]</xref></p>
        <p>The underlying host factors largely determine the pathogenesis of complicated UTIs. Impairment of the immune system and voiding dysfunction from autonomic neuropathy may predispose patients with diabetes to develop UTIs. In renal insufficiency, accumulation of uremic toxins may reduce host defenses, and decreased renal blood flow may impair antimicrobial clearance. Kidney stones may cause an obstruction and provide a potential nidus of infection. In the setting of urinary catheterization, internal and external biofilms may form on the catheter, and pathogens may persist in retained pools of urine in the urinary bladder.<xref ref-type="bibr" rid="article-20220.r14">[14]</xref></p>
        <p>The overwhelming identifiable bacteria causing most cases of cystitis is <italic toggle="yes">Escherichia coli</italic> (from 75% to 95% of cases). Other organisms causing cystitis include <italic toggle="yes">Klebsiella pneumoniae</italic> and <italic toggle="yes">Proteus mirabilis</italic>. (<italic toggle="yes">Klebsiella</italic> is the most common cause of UTIs after <italic toggle="yes">E. coli</italic>.) Patients with recent hospitalizations or prior treatment for a UTI may present with Pseudomonas, enterococci, and staphylococci, such as <italic toggle="yes">S. saprophyticus</italic>. Many other organisms, such as lactobacilli, Group B streptococci, and coagulase-negative staphylococci, are generally considered contaminants unless there are very high numbers of a single organism where an actual infection is possible.<xref ref-type="bibr" rid="article-20220.r15">[15]</xref></p>
      </sec>
      <sec id="article-20220.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Acute cystitis often presents urinary symptoms, including dysuria, urinary frequency, urgency, suprapubic pain or tenderness, and occasionally hematuria. Based on a systematic review examining the history and examination findings of women with uncomplicated UTI, the combination of dysuria and urinary frequency in the absence of vaginal discharge or irritation is highly predictive of uncomplicated cystitis (90% correlation).<xref ref-type="bibr" rid="article-20220.r16">[16]</xref> Symptoms may be subtle or atypical in the very young and the very old. Urine cloudiness or a "foul odor" in the absence of other signs or symptoms is generally insufficient to justify a diagnosis of cystitis.<xref ref-type="bibr" rid="article-20220.r17">[17]</xref></p>
        <p>Patients with complicated acute cystitis will often present similarly to uncomplicated cystitis. Specific patient populations with complicated cystitis may have atypical symptoms. For example, patients with multiple sclerosis occasionally present with acute neurologic deterioration, while those with a spinal cord injury may present with autonomic dysfunction or increased spasticity.</p>
        <p>Cystitis may be differentiated from pyelonephritis by the absence of systemic findings such as fever, chills, or sepsis. Findings such as flank pain, costovertebral angle tenderness, nausea, and vomiting indicate upper UTI or pyelonephritis.</p>
        <p>When evaluating a patient with symptoms of UTI, it is important to obtain a history of any previous episode of UTI, any recent antibiotic use, or any other risk factors that may predispose one to complicated infection such as diabetes, immunocompromised status, recent urologic procedures or instrumentation, renal transplantation, history of kidney stones, anatomical or functional urinary tract abnormalities, or pregnancy.</p>
        <p>A pelvic examination is important in evaluating women with cystitis, especially if they have recurrent urinary tract infections. Recurrent infections are defined as two documented UTIs within six months or three in one year. Management of recurrent urinary infections is discussed elsewhere, particularly in the American Urological Association Guidelines on Recurrent Urinary Tract Infections.<xref ref-type="bibr" rid="article-20220.r18">[18]</xref>&#x000a0;Recurrent infections with the identical organism (called a relapsing infection) suggest a urinary stone. In men, recurrent infections may also indicate chronic bacterial prostatitis. Positive urine cultures are necessary to make a definitive diagnosis of recurrent or relapsing UTIs.&#x000a0;</p>
        <p>In frail and debilitated patients, many general symptoms, such as a change of mental or functional status, fevers, chills, and falls, are associated with a presumptive diagnosis of UTI. Recent evidence suggests that only urinary changes (color changes, odor, gross hematuria) and acute dysuria were reliably associated with documented UTIs.<xref ref-type="bibr" rid="article-20220.r17">[17]</xref>&#x000a0;Changes in urinary odor and color alone suggest bacteriuria, but the evidence is lacking that antibiotic treatment is warranted until or unless other symptoms, such as fever, develop. Recommended treatment for changes in mental status is hydration (for possible dehydration), observation, and assessment for other causes.<xref ref-type="bibr" rid="article-20220.r19">[19]</xref>&#x000a0;Mental status changes may or may not suggest a UTI in these patients, as studies are conflicting.<xref ref-type="bibr" rid="article-20220.r17">[17]</xref><xref ref-type="bibr" rid="article-20220.r20">[20]</xref></p>
      </sec>
      <sec id="article-20220.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of acute cystitis is usually made clinically in a patient with signs and symptoms consistent with a lower UTI in combination with laboratory evidence of pyuria and/or nitrites. Physical examination findings are often not necessary for the diagnosis of cystitis but may be more important for patients with pyelonephritis or vaginitis. Often in young, non-pregnant women with typical cystitis symptoms, especially in the absence of vaginal discharge or irritation, clinical suspicion may be sufficient in making the diagnosis and initiating treatment without laboratory confirmation.<xref ref-type="bibr" rid="article-20220.r1">[1]</xref><xref ref-type="bibr" rid="article-20220.r21">[21]</xref><xref ref-type="bibr" rid="article-20220.r22">[22]</xref><xref ref-type="bibr" rid="article-20220.r23">[23]</xref>&#x000a0;However, it is highly recommended that a urinalysis and a urine culture be obtained prior to starting antibiotic treatment. If the patient does not improve on the initial antibiotic, there will be inadequate clinical information to optimally manage changes in treatment.&#x000a0;</p>
        <p>Urinalysis, when indicated, is the most important laboratory test in diagnosing a UTI. A clean catch sample is usually sufficient, but if an uncontaminated specimen with few epithelial cells cannot otherwise be obtained, as in some morbidly obese women, a quick urethral catheterization should be considered. The risk of UTI from a single urethral catheterization in previously uninfected women is only about 1%.<xref ref-type="bibr" rid="article-20220.r24">[24]</xref></p>
        <p>The visual appearance of the urine is notoriously unreliable when diagnosing a UTI. Clear urine may be grossly infected, and cloudy urine may be sterile with the "cloudiness" caused by calcium phosphate debris or protein. One simple test is to add a few drops of glacial acetic acid to a test tube of the cloudy urine specimen. If this causes the "cloudiness" to disappear, the urine is most likely full of calcium phosphate debris.</p>
        <p>Pyuria, which is the presence of at least 10 white blood cells (WBCs)/HPF or leukocytes in an unspun midstream urine specimen, is almost always present. The absence of pyuria is suggestive of an alternative diagnosis.</p>
        <p>Urinary dipsticks may also be used in the diagnosis of UTI. They detect the presence of leukocyte esterase, an enzyme produced by leukocytes, and nitrites, which indicate the presence of&#x000a0;<italic toggle="yes">Enterobacteriaceae</italic>. (Nitrates are broken down to nitrites only in the presence of bacteria, so a positive nitrite test indicates or is strongly suggestive of bacteriuria).<xref ref-type="bibr" rid="article-20220.r24">[24]</xref>&#x000a0;Only <italic toggle="yes">Acinetobacter</italic>, <italic toggle="yes">Pseudomonas</italic>, and <italic toggle="yes">Enterococcus</italic> typically fail to convert nitrates to nitrites.<xref ref-type="bibr" rid="article-20220.r25">[25]</xref> A positive dipstick test for leukocyte esterase or nitrites is helpful and confirmatory in patients with typical symptoms of acute cystitis. A negative dipstick test, however, does not reliably rule out a diagnosis of UTI.<xref ref-type="bibr" rid="article-20220.r6">[6]</xref><xref ref-type="bibr" rid="article-20220.r26">[26]</xref><xref ref-type="bibr" rid="article-20220.r27">[27]</xref>&#x000a0;</p>
        <p>It is reasonable to treat patients with UTI symptoms with antibiotics based on positive nitrites, but other diagnoses should be considered if the leukocyte esterase is negative.<xref ref-type="bibr" rid="article-20220.r28">[28]</xref>&#x000a0;The positive predictive value of having both a positive leukocyte esterase and nitrites is quite high at 85%, with an equally high negative predictive value of 92%.<xref ref-type="bibr" rid="article-20220.r28">[28]</xref></p>
        <p>A urine culture is beneficial for identifying etiologic pathogens and for determining antimicrobial susceptibility profiles. Greater than or equal to 100,000 CFU (colony forming units)/mL indicates clinically relevant bacteriuria, but the growth of greater than or equal to 1,000 CFU is considered significant in men and from samples obtained through straight catheterization of the bladder. Less than 100,000 CFU/mL does not rule out a urinary tract infection.<xref ref-type="bibr" rid="article-20220.r15">[15]</xref><xref ref-type="bibr" rid="article-20220.r29">[29]</xref>&#x000a0;In cases of acute uncomplicated cystitis, however, urine cultures are often considered unnecessary and not routinely done, although they can be very helpful in patients with persistent symptoms and presumed treatment failures, especially in view of the increasing rates of antibiotic resistance.<xref ref-type="bibr" rid="article-20220.r24">[24]</xref></p>
        <p>Urinalyses and urine cultures must be performed prior to antibiotic therapy in all men with acute cystitis symptoms and women with risk factors for complicated UTIs. They are also indicated in patients with atypical symptoms, those who do not respond to treatment, and where symptoms recur within 2 to 4 weeks.<xref ref-type="bibr" rid="article-20220.r11">[11]</xref> A pregnancy test should be done on women of childbearing age.</p>
        <p>Men who have recurrent episodes of cystitis should undergo an evaluation for prostatitis. In young men who are sexually active with a single episode of cystitis, urologic evaluation may not be indicated. Risk factors for a complicated UTI should prompt a urologic evaluation and workup.&#x000a0;</p>
        <p>Multiple drug-resistant organisms are becoming an increasingly difficult problem. They are defined as bacteria resistant to three or more different categories of antibiotics. Antibiotic drug resistance is a primary reason to obtain urine cultures in any potentially complicated or difficult infection and in all high-risk patients with urinary infections.&#x000a0;</p>
        <p>Patients with complicated cystitis who do not respond after 48 to 72 hours of appropriate antimicrobial treatment will require further evaluation through radiographic imaging of the upper urinary tract.<xref ref-type="bibr" rid="article-20220.r11">[11]</xref> This may be in the form of computed tomography (CT) or ultrasonography. CT imaging is usually the test of choice and is more sensitive in detecting abnormal processes that may interfere with treatment response, such as urinary obstruction, stones, diverticula, or abscess formation. Ultrasound of the kidneys, especially when combined with a KUB (short for kidneys, ureters, and bladder: i.e., a flat plate of the abdomen), may be adequate in patients who should minimize radiation exposure or otherwise avoid CT imaging.<xref ref-type="bibr" rid="article-20220.r11">[11]</xref> A cystoscopy may optionally be done as well.&#x000a0;</p>
      </sec>
      <sec id="article-20220.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Acute cystitis is treated with antibiotic therapy. The selection of an antimicrobial agent depends on a patient&#x02019;s risk factors for infection with multiple drug-resistant organisms. Patients who are at low risk for resistant etiologic organisms are treated with one of the first-line or preferred antimicrobial agents, which include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Nitrofurantoin 100 mg twice a day for 5 to 7 days</p>
          </list-item>
          <list-item>
            <p>Sulfamethoxazole-trimethoprim (SMX-TMP) double-strength twice a day for three days (if local antibiotic resistance is &#x0003c;20%)</p>
          </list-item>
          <list-item>
            <p>Fosfomycin 3 gm as a single oral dose</p>
          </list-item>
          <list-item>
            <p>Pivmecillinam 400 mg twice a day for 5 to 7 days (not approved in the US)<xref ref-type="bibr" rid="article-20220.r30">[30]</xref></p>
          </list-item>
        </list>
        <p><bold>Nitrofurantoin</bold> is generally the first choice antibiotic for simple cystitis. It does not promote resistance or yeast overgrowth, has a high clinical cure rate of 79% to 92%, and can be safely used even in older patients as long as their glomerular filtration rate is &#x0003e;60 ml/min. It has little tissue penetration and therefore is inappropriate for patients with fevers, pyelonephritis, or other evidence of systemic illness.<xref ref-type="bibr" rid="article-20220.r31">[31]</xref><xref ref-type="bibr" rid="article-20220.r32">[32]</xref>&#x000a0;Nitrofurantoin is less active against organisms in the Proteeae group (<italic toggle="yes">Proteus</italic>, <italic toggle="yes">Morganella</italic>, and <italic toggle="yes">Providencia</italic>) which produce urease that raises the urinary pH. It has been shown that nitrofurantoin is less effective in UTIs where the urine pH is 8 or higher.<xref ref-type="bibr" rid="article-20220.r33">[33]</xref>&#x000a0;Nitrofurantoin is a bacteriostatic rather than a bacteriocidal drug. Therefore, it should not be given for less than five days.<xref ref-type="bibr" rid="article-20220.r24">[24]</xref></p>
        <p><bold>Sulfamethoxazole-Trimethoprim (SMX-TMP)</bold> is recommended when local resistance to the antibiotic is &#x0003c;20%. It has good tissue penetration, including into the prostate. The overall clinical cure rate is reported as 79% to 100%.<xref ref-type="bibr" rid="article-20220.r34">[34]</xref><xref ref-type="bibr" rid="article-20220.r35">[35]</xref> Trimethoprim can be used alone with similar efficacy in patients with a sulfa allergy.<xref ref-type="bibr" rid="article-20220.r36">[36]</xref>&#x000a0;Unfortunately, resistance to SMX-TMP tends to develop relatively rapidly.<xref ref-type="bibr" rid="article-20220.r37">[37]</xref></p>
        <p><bold>Fosfomycin</bold> has a similar overall clinical cure rate as nitrofurantoin.<xref ref-type="bibr" rid="article-20220.r38">[38]</xref> It is often not included in urine culture results and is therefore not used frequently in the US. However, it retains activity against many drug-resistant organisms, including <italic toggle="yes">E. coli</italic> and Enterococcus; therefore, it is not recommended for routine use initially. It can be used for both Gram-negative and Gram-positive organisms, including vancomycin-resistant strains. It is less effective against <italic toggle="yes">Klebsiella</italic> and <italic toggle="yes">Pseudomonas</italic>. Also, it is inappropriate for use in real or suspected pyelonephritis due to insufficient renal tissue levels. It is a bacteriocidal drug that is generally underutilized.</p>
        <p>It works by interfering with bacterial cell wall synthesis but in a manner distinct from beta-lactams. It is a unique antibiotic with relatively little resistance despite being available since 1969. It has been used off-label for prostatitis and has been shown to increase the immune response. It also penetrates biofilms well. While the usual dose is a single 3-gram packet, up to 3 doses can be used 2-3 days apart in complex situations.<xref ref-type="bibr" rid="article-20220.r39">[39]</xref>&#x000a0;Fosfomycin can safely be used in pregnancy (FDA category B), where its single-dosing schedule is advantageous.<xref ref-type="bibr" rid="article-20220.r40">[40]</xref>&#x000a0;Recent studies have suggested that fosfomycin can also be useful in complicated UTIs and pyelonephritis, but additional studies are needed for confirmation before this can be generally recommended.<xref ref-type="bibr" rid="article-20220.r40">[40]</xref><xref ref-type="bibr" rid="article-20220.r41">[41]</xref><xref ref-type="bibr" rid="article-20220.r42">[42]</xref></p>
        <p><bold>Pivmecillinam</bold> is not available in the US but is used elsewhere, particularly in Nordic countries, due to its very low reported bacterial resistance.<xref ref-type="bibr" rid="article-20220.r43">[43]</xref>&#x000a0;It is a penicillin with an extended spectrum that is useful only in the urinary tract. Like nitrofurantoin, it does not significantly promote antibiotic resistance but is also not useful in pyelonephritis or systemic infections due to poor tissue penetration.<xref ref-type="bibr" rid="article-20220.r44">[44]</xref>&#x000a0;</p>
        <p>Complicated infections are generally treated with 10 to 14 days of antibiotics. People with diabetes will be at increased risk for yeast infections during and immediately following antibiotic treatment, so appropriate steps should be taken.&#x000a0;</p>
        <p><bold>Antimicrobial selection</bold> should be individualized based on patient factors, including allergies, adverse effects, tolerability, local bacterial resistance patterns, potential drug interactions, cost and insurance coverage, renal function, compliance history, and recent use of a specific antimicrobial agent within the preceding three months. Nitrofurantoin should not be used in patients with creatinine clearance or a glomerular filtration rate (GFR) of less than 60 mL per minute, while SMX-TMP should be avoided in places where regional resistance is greater than 20%, as well as in patients with allergies to sulfa. Risk factors for such resistance include recent prior contact with healthcare, use of SMX-TMP within the previous six months, and travel, especially internationally. The suspicion of pyelonephritis or a complicated UTI also precludes the use of nitrofurantoin, fosfomycin, norfloxacin, pivmecillinam, and possibly fosfomycin because of their poor penetration into renal tissues.<xref ref-type="bibr" rid="article-20220.r6">[6]</xref><xref ref-type="bibr" rid="article-20220.r45">[45]</xref></p>
        <p><bold>Alternative or second-line antimicrobial agents</bold> are used in acute cystitis patients&#x000a0;with factors or circumstances that prevent using the first-line agents. A 5 to 7-day course of an oral beta-lactam such as amoxicillin-clavulanate 500 mg twice daily, cefpodoxime 100 mg twice daily, cefdinir 300 mg twice daily, cefadroxil 500 mg twice daily, or cephalexin 500 mg twice daily (although this agent is less well-studied) is usually preferred. If beta-lactam agents are contraindicated, doxycycline (a tetracycline) or a fluoroquinolone such as ciprofloxacin, norfloxacin, or levofloxacin for three days (simple UTIs) or 7 to 14 days (complicated UTIs) may be used. Global resistance to SMX-TMP and amoxicillin are approaching or exceeding 20%, making these agents less useful in many geographical areas.&#x000a0;</p>
        <p>Another approach is to start patients initially on a single dose of an IV parenteral agent while in the office or ER, such as ceftriaxone 1 gram, ertapenem 1 gram, or gentamycin/tobramycin 5 mg/kg. (Of these, ceftriaxone is preferred, and the aminoglycosides are reserved for those who cannot be safely given either of the other choices.) This is followed by 10&#x000a0;to 14 days of an oral antibiotic depending on the final urine culture results.&#x000a0;</p>
        <p>Gentamicin bladder instillations can also be used to help treat UTIs, but this requires catheterization so it is generally not preferred except for selected patients, usually those with neurogenic bladders or on self-catheterization programs.<xref ref-type="bibr" rid="article-20220.r11">[11]</xref><xref ref-type="bibr" rid="article-20220.r46">[46]</xref><xref ref-type="bibr" rid="article-20220.r47">[47]</xref>&#x000a0;The suggested dosage is 30&#x000a0;to 60 cc of 480 mg of gentamicin/liter of normal saline or 80 mg of gentamicin&#x000a0;in 50&#x000a0;to 60 mL of normal saline.<xref ref-type="bibr" rid="article-20220.r11">[11]</xref>&#x000a0;Tobramycin at the same dosage or neomycin/bacitracin/polymixin B (40 mg/mL) may also be used, but gentamicin has been the most studied for this purpose. Chlorhexidine and povidone-iodine bladder instillations have also been effective in reducing bacteriuria and UTIs, but not neomycin/bacitracin/polymixin B.<xref ref-type="bibr" rid="article-20220.r11">[11]</xref><xref ref-type="bibr" rid="article-20220.r48">[48]</xref>&#x000a0;Bladder instillation therapy can be a reasonable option for patients already on self-intermittent catheterization with recurrent or intractable UTIs.<xref ref-type="bibr" rid="article-20220.r48">[48]</xref></p>
        <p>Mandelamine can be a useful prophylactic agent, especially for recurrent multi-drug resistant infections.<xref ref-type="bibr" rid="article-20220.r11">[11]</xref><xref ref-type="bibr" rid="article-20220.r49">[49]</xref> Given twice daily (1,000 mg BID), mandelamine is converted to formaldehyde in the bladder if the urine is acidic (5.5 or less).<xref ref-type="bibr" rid="article-20220.r50">[50]</xref>&#x000a0;It is usually given together with 500 to 1,000 mg of vitamin C to maintain urinary acidity.<xref ref-type="bibr" rid="article-20220.r11">[11]</xref>&#x000a0;Mandelamine should not be used if the glomerular filtration rate (GFR) is &#x0003c;10 mL/min or if the urinary pH cannot be maintained at 5.5 or less. It also is not recommended for use together with sulfonamides due to potential precipitation.<xref ref-type="bibr" rid="article-20220.r11">[11]</xref></p>
        <p>D-mannose has also been used with some success as a non-antibiotic-based UTI prophylactic agent, with some studies and meta-analyses suggesting equivalence with antibiotic prophylaxis.<xref ref-type="bibr" rid="article-20220.r51">[51]</xref><xref ref-type="bibr" rid="article-20220.r52">[52]</xref><xref ref-type="bibr" rid="article-20220.r53">[53]</xref>&#x000a0;It is well tolerated with few side effects but is not appropriate for treating an active UTI. The suggested dosage is 2 grams daily. While it seems to be generally helpful as a prophylactic agent, the available data and studies are far from conclusive.<xref ref-type="bibr" rid="article-20220.r51">[51]</xref><xref ref-type="bibr" rid="article-20220.r52">[52]</xref><xref ref-type="bibr" rid="article-20220.r53">[53]</xref><xref ref-type="bibr" rid="article-20220.r54">[54]</xref></p>
        <p><bold>Urine culture and sensitivity testing</bold> are required to guide antimicrobial regimens in patients at risk for multiple drug-resistant (MDR) organisms. Risk factors include a previous MDR isolate (resistant to three or more antimicrobial classes), recent stay in a healthcare facility, recent travel to areas with a high prevalence of MDR organisms, or use of broad-spectrum antimicrobial agents in the previous three months. The appropriate empiric regimen includes nitrofurantoin, SMX-TMP, fosfomycin, and pivmecillinam (if available). An alternative approach would be to defer treatment until culture and susceptibility results are available, especially if the use of any of the above first-line agents is precluded for any reason.</p>
        <p>Symptomatic treatment with analgesics may be used in patients with severe dysuria. Phenazopyridine is a urinary analgesic used in the short-term treatment of urinary dysuria or discomfort, but it is not therapeutic and will not affect the clinical course of an infection.</p>
        <p><bold>Cystitis in men</bold> is relatively uncommon and not very well studied. In a healthy man without any risk factors for a complicated UTI or any symptoms suggestive of infection outside the bladder, the treatment approach should be the same as in women with a complicated UTI. For men with severe symptoms, anatomical or urologic abnormalities, or suspicion of prostate involvement, fluoroquinolones have been recommended for initial use as empiric therapy, pending culture and susceptibility testing results and local quinolone resistance patterns. Quinolones are preferred initial agents, when possible, due to their broad spectrum of activity and high tissue penetration levels. Doxycycline, SMX-TMP, and cephalosporins may also be used initially, which help minimize quinolone resistance. All men with clearly diagnosed UTIs have generally been considered complicated infections and are at risk for developing chronic prostatitis, which may not become clinically apparent for weeks or even months after the initial infection. For this reason, some recommend using prostate-penetrating antibiotics (doxycycline, SMX-TMP, quinolones) in all men with UTIs for at least four to six weeks to allow for the buildup of adequate antibiotic concentrations inside the prostate and reduce the likelihood of developing subsequent chronic prostatitis.<xref ref-type="bibr" rid="article-20220.r11">[11]</xref>&#x000a0;</p>
        <p>Patients who do not respond to an appropriate antimicrobial regimen after 48 to 72 hours or who have a recurrence of symptoms within a few weeks will require further evaluation, including consideration of other potential causes or infection with resistant organisms. Urine culture and susceptibility testing should be obtained, and patients must be treated with a different empiric antimicrobial agent with subsequent tailoring of the regimen based on susceptibility results.<xref ref-type="bibr" rid="article-20220.r6">[6]</xref><xref ref-type="bibr" rid="article-20220.r11">[11]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-20220.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>In female patients with dysuria, differential diagnoses include vaginitis and urethritis. Vaginitis is usually associated with vaginal discharge, dyspareunia, and pruritus. Its causes include bacterial vaginosis, trichomoniasis, or yeast infection. Painful bladder syndrome may be considered in patients with persistent symptoms of bladder discomfort but with no evidence of infectious etiology. This is, however, a diagnosis of exclusion. Prostatitis must be ruled out in men with lower UTI symptoms, especially when associated with fever, malaise, perineal pain, or obstructive urinary symptoms. Recurrent UTIs in male patients should heighten suspicion of chronic bacterial prostatitis.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Painful bladder syndrome</bold> - No evidence of infection (pyuria, bacteriuria, positive urine cultures) but symptoms of frequency, urgency, and dysuria.; it is usually a diagnosis of exclusion.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Pelvic inflammatory disease</bold> - This is associated with pelvic and lower abdominal pain, fever, and possible cervical discharge.</p>
          </list-item>
          <list-item>
            <p><bold>Prostatitis</bold> - May present with ejaculatory pain and/or vague pelvic discomfort along with a soft, boggy, tender prostate on rectal exam. Urinalysis is usually negative.</p>
          </list-item>
          <list-item>
            <p><bold>Vaginitis</bold> - Usually associated with vaginal discharge, itching, odor, dyspareunia, and possibly dysuria. Typically no urinary urgency or frequency.</p>
          </list-item>
          <list-item>
            <p><bold>Vaginitis, atrophic (hormonal)</bold> - This condition presents in post-menopausal women&#x000a0;and is associated with vaginal dryness, dyspareunia, vaginal discharge (thin, watery), pale labia, and vaginal lining.</p>
          </list-item>
          <list-item>
            <p><bold>Urethritis</bold> - White cells (pyuria) present on urinalysis but no bacteriuria. Sexually active women are at high risk.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20220.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with uncomplicated cystitis typically have an improvement in symptoms within three days after initiation of antibiotic therapy. Recurrent cystitis occurs in 25% of women within six months after their first UTI, and the rate increases in women with more than one prior UTI. Complications are rare, especially in patients who are appropriately treated. Bacteremia and sepsis from uncomplicated cystitis are uncommon.</p>
        <p>Emphysematous cystitis is a rare but serious complication of a lower urinary tract infection. It is associated with gas formation in the bladder wall and&#x000a0;is potentially fatal if not properly managed. Emphysematous cystitis is more likely to cause abdominal pain (80%) than simple cystitis (50%); pneumaturia will likely be present in about 70% of patients, and half will have bacteremia. The diagnosis is most reliably made with a CT scan. The primary risk factor is diabetes which is present in about 2/3 of affected patients. Other risk factors include female gender, immunocompromised conditions, urinary abnormalities, urinary obstruction or retention, indwelling urinary catheter, age over 60, and chronic UTIs.<xref ref-type="bibr" rid="article-20220.r55">[55]</xref><xref ref-type="bibr" rid="article-20220.r56">[56]</xref>&#x000a0;</p>
        <p>Treatment is primarily medical with antibiotics, but catheter drainage should be used in cases of retention, incomplete bladder emptying, or significant hematuria. About 10% of patients will develop a&#x000a0;necrotizing infection of the bladder wall and will require surgical intervention involving partial or complete resection.<xref ref-type="bibr" rid="article-20220.r56">[56]</xref></p>
      </sec>
      <sec id="article-20220.s11" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Pyelonephritis</p>
          </list-item>
          <list-item>
            <p>Renal or perinephric abscess formation</p>
          </list-item>
          <list-item>
            <p>Renal vein thrombosis</p>
          </list-item>
          <list-item>
            <p>Sepsis</p>
          </list-item>
          <list-item>
            <p>Acute renal failure</p>
          </list-item>
          <list-item>
            <p>Emphysematous pyelonephritis</p>
          </list-item>
          <list-item>
            <p>Prostatitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20220.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with cystitis should be made aware of the importance of adherence to their prescribed antibiotic regimen. Increasing oral fluid intake should also be encouraged. In sexually active patients, post-intercourse voiding may help to reduce recurrent infection. Patients should be advised to follow up if their symptoms worsen or do not improve after treatment with an antibiotic has started.</p>
      </sec>
      <sec id="article-20220.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Consider bladder instillation therapy for patients on dialysis and those performing regular intermittent self-catheterization.</p>
        <p>Mandelamine with vitamin C or D-mannose is a reasonable option for UTI prevention in selected patients, although more studies are needed to confirm their effectiveness.</p>
        <p>Gepotidacin is a new antibiotic in a novel chemical class called triazaacenaphthylene.<xref ref-type="bibr" rid="article-20220.r57">[57]</xref>&#x000a0;It selectively binds and inhibits bacterial topoisomerase IV and DNA gyrase, preventing or significantly slowing bacterial DNA replication.<xref ref-type="bibr" rid="article-20220.r58">[58]</xref><xref ref-type="bibr" rid="article-20220.r59">[59]</xref>&#x000a0;Unlike fluoroquinolones, gepotidacin&#x000a0;contains no fluorine, appears not to cause any arthropathy, and utilizes a unique mechanism of action.<xref ref-type="bibr" rid="article-20220.r58">[58]</xref><xref ref-type="bibr" rid="article-20220.r59">[59]</xref>&#x000a0;It is effective against many target organisms like <italic toggle="yes">E. coli</italic> and <italic toggle="yes">Neisseria gonorrhea</italic> that are resistant to current antibiotics.<xref ref-type="bibr" rid="article-20220.r57">[57]</xref><xref ref-type="bibr" rid="article-20220.r60">[60]</xref>&#x000a0;If approved by the FDA, it would be the&#x000a0;first new antibiotic for UTIs in over 20 years. The initial indication is likely for simple UTIs as its potential clinical application in complicated urinary tract infections, prostatitis, and urinary sepsis is still to be determined.</p>
        <p>Investigationally, initial attempts to make vaccines to help prevent urinary tract infections have only been marginally successful, but research in this area is continuing.<xref ref-type="bibr" rid="article-20220.r61">[61]</xref><xref ref-type="bibr" rid="article-20220.r62">[62]</xref><xref ref-type="bibr" rid="article-20220.r63">[63]</xref>&#x000a0;Some are made from whole bacterial cells, while others are based on <italic toggle="yes">E. coli</italic> bioconjugates or <italic toggle="yes">E.coli</italic> type 1 fimbrial adhesive protein.<xref ref-type="bibr" rid="article-20220.r64">[64]</xref><xref ref-type="bibr" rid="article-20220.r65">[65]</xref>&#x000a0;Another approach to an experimental vaccine targets four&#x000a0;outer membrane receptors involved in <italic toggle="yes">E. coli</italic> iron absorption (IreA, FyuA, IutA, and Hma), which are critical to the survival of the pathogen.<xref ref-type="bibr" rid="article-20220.r66">[66]</xref>&#x000a0;In Europe, an oral immune system stimulant is currently available and has demonstrated a 95% reduction in <italic toggle="yes">E. coli</italic> recurrences.<xref ref-type="bibr" rid="article-20220.r67">[67]</xref>&#x000a0;</p>
        <p>Improving personal hygiene for many women appears to be helpful. Optimal personal hygiene suggestions include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Wash hands before wiping after voiding.</p>
          </list-item>
          <list-item>
            <p>Use adult or baby wipes instead of plain toilet paper.</p>
          </list-item>
          <list-item>
            <p>Wiping just once, from front to back, after voiding.</p>
          </list-item>
          <list-item>
            <p>Use showers instead of baths.</p>
          </list-item>
          <list-item>
            <p>Use a non-toxic liquid soap with minimal chemicals or perfumes to clean the vaginal area. Any liquid soap or shampoo safe for babies is likely to be acceptable.</p>
          </list-item>
          <list-item>
            <p>Use soft cotton or microfiber washcloths rather than hands, nylon, or luffa pads for soap application while washing.</p>
          </list-item>
          <list-item>
            <p>Wash the vaginal opening first to avoid contamination or movement of bacteria to this critical area.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20220.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Cystitis is a commonly encountered disorder by primary care clinicians. The diagnosis and management are relatively straightforward in most patients. However, there are other patients with structural abnormalities, diabetes, and patients with spinal cord problems who are more difficult to manage&#x000a0;due to the risk of recurrent cystitis. Hence, an interprofessional team approach is necessary to improve outcomes.</p>
        <p>An interprofessional healthcare team approach is essential in managing cystitis. Patient education is the key, and all clinicians who manage patients with cystitis should encourage an increase in fluid intake. Several studies show that increased fluid intake reduces the risk of recurrent infections. The pharmacist should educate the patient on medication compliance, verify all drugs are appropriately dosed and perform medication reconciliation to preclude any drug-drug interactions. The nurse should educate sexually active women to void after sexual intercourse as this has been shown to lessen the risk of a bacterial infection. Patients with recurrent infections should be referred to a urologist for a more extensive workup. Only with open communication between members of the interprofessional team can the morbidity of cystitis be lowered; therefore, it is incumbent on any team member who notices an issue or a change in the patient's status to document their findings and reach out to the appropriate team members for corrective action. [Level 5]</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Patients with uncomplicated cystitis typically have an improvement in symptoms within three days after initiation of antibiotic therapy. However, recurrent cystitis occurs in 25% of women within six months after the first UTI, and the rate increases in women with more than one prior UTI. Complications are rare, especially in patients who are appropriately treated. When males present with a first-time episode, a referral to a urologist should be made to ensure no structural or functional abnormality. Immunosuppressed individuals&#x000a0;or those with diabetes who require chronic catheterization or take steroids regularly have a greater potential to develop sepsis. They should be closely monitored and managed by an infectious disease specialist.<xref ref-type="bibr" rid="article-20220.r68">[68]</xref></p>
      </sec>
      <sec id="article-20220.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20220&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20220">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/kidney-health/cystitis-urinary-tract-infection/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20220">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20220/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20220">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20220.s16">
        <title>References</title>
        <ref id="article-20220.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldman</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Urinary tract infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.</article-title>
            <source>Clin Transplant</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>9</issue>
            <fpage>e13507</fpage>
            <pub-id pub-id-type="pmid">30793386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vellinga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Cormican</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smyth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Healy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Little</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Devane</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>COSUTI: a protocol for the development of a core outcome set (COS) for interventions for the treatment of uncomplicated urinary tract infection (UTI) in adults.</article-title>
            <source>Trials</source>
            <year>2019</year>
            <month>Feb</month>
            <day>07</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>106</fpage>
            <pub-id pub-id-type="pmid">30732617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Behzadi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Behzadi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yazdanbod</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aghapour</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Akbari Cheshmeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salehian Omran</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>A survey on urinary tract infections associated with the three most common uropathogenic bacteria.</article-title>
            <source>Maedica (Bucur)</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-5</page-range>
            <pub-id pub-id-type="pmid">21977133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Byron</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Urinary Tract Infection.</article-title>
            <source>Vet Clin North Am Small Anim Pract</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>49</volume>
            <issue>2</issue>
            <fpage>211</fpage>
            <page-range>211-221</page-range>
            <pub-id pub-id-type="pmid">30591189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karamali</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shafabakhsh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ghanbari</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Eftekhar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Asemi</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Molecular pathogenesis of interstitial cystitis/bladder pain syndrome based on gene expression.</article-title>
            <source>J Cell Physiol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>234</volume>
            <issue>8</issue>
            <fpage>12301</fpage>
            <page-range>12301-12308</page-range>
            <pub-id pub-id-type="pmid">30609029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rank</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Lodise</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Avery</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bankert</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dobson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dumyati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hassett</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pearsall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lubowski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carreno</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial Susceptibility Trends Observed in Urinary Pathogens Obtained From New York State.</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>5</volume>
            <issue>11</issue>
            <fpage>ofy297</fpage>
            <pub-id pub-id-type="pmid">30539040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Talan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Takhar</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Krishnadasan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abrahamian</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Mower</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Moran</surname>
                <given-names>GJ</given-names>
              </name>
              <collab>EMERGEncy ID Net Study Group</collab>
            </person-group>
            <article-title>Fluoroquinolone-Resistant and Extended-Spectrum &#x003b2;-Lactamase-Producing Escherichia coli Infections in Patients with Pyelonephritis, United States(1).</article-title>
            <source>Emerg Infect Dis</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>9</issue>
            <fpage>1594</fpage>
            <page-range>1594-603</page-range>
            <pub-id pub-id-type="pmid">27532362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colpan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Clabots</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Anway</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Thao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kuskowski</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Tchesnokova</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sokurenko</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>JR</given-names>
              </name>
              <collab>VICTORY (Veterans Influence of Clonal Types on Resistance: Year 2011) Investigators</collab>
            </person-group>
            <article-title>Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans.</article-title>
            <source>Clin Infect Dis</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>57</volume>
            <issue>9</issue>
            <fpage>1256</fpage>
            <page-range>1256-65</page-range>
            <pub-id pub-id-type="pmid">23926176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kranz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lebert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schneidewind</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mandraka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kunze</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Helbig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vahlensieck</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Naber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schmiemann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wagenlehner</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention.</article-title>
            <source>Urol Int</source>
            <year>2018</year>
            <volume>100</volume>
            <issue>3</issue>
            <fpage>271</fpage>
            <page-range>271-278</page-range>
            <pub-id pub-id-type="pmid">29539622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Su&#x000e1;rez Fern&#x000e1;ndez</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Ridao Cano</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>&#x000c1;lvarez Santamarta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gago Fraile</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blake</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az Corte</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A Current Review of the Etiology, Clinical Features, and Diagnosis of Urinary Tract Infection in Renal Transplant Patients.</article-title>
            <source>Diagnostics (Basel)</source>
            <year>2021</year>
            <month>Aug</month>
            <day>12</day>
            <volume>11</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">34441390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sabih</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Complicated Urinary Tract Infections</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">28613784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krieger</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Simonsen</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Urinary tract infections in healthy university men.</article-title>
            <source>J Urol</source>
            <year>1993</year>
            <month>May</month>
            <volume>149</volume>
            <issue>5</issue>
            <fpage>1046</fpage>
            <page-range>1046-8</page-range>
            <pub-id pub-id-type="pmid">8483206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tyagi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Janicki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chancellor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yoshimura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chermansky</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in imaging and understanding interstitial cystitis.</article-title>
            <source>F1000Res</source>
            <year>2018</year>
            <volume>7</volume>
            <pub-id pub-id-type="pmid">30473772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sim&#x000f5;es</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borges</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and Impact of Biofilms on Bloodstream and Urinary Tract Infections: A Systematic Review and Meta-Analysis.</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2021</year>
            <month>Jul</month>
            <day>08</day>
            <volume>10</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">34356749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hooton</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Stapleton</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Voided midstream urine culture and acute cystitis in premenopausal women.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Nov</month>
            <day>14</day>
            <volume>369</volume>
            <issue>20</issue>
            <fpage>1883</fpage>
            <page-range>1883-91</page-range>
            <pub-id pub-id-type="pmid">24224622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bent</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nallamothu</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Simel</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Fihn</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Saint</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Does this woman have an acute uncomplicated urinary tract infection?</article-title>
            <source>JAMA</source>
            <year>2002</year>
            <month>May</month>
            <day>22-29</day>
            <volume>287</volume>
            <issue>20</issue>
            <fpage>2701</fpage>
            <page-range>2701-10</page-range>
            <pub-id pub-id-type="pmid">12020306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Juthani-Mehta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quagliarello</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Perrelli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Towle</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Van Ness</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Tinetti</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical features to identify urinary tract infection in nursing home residents: a cohort study.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>963</fpage>
            <page-range>963-70</page-range>
            <pub-id pub-id-type="pmid">19490243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ackerman</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chughtai</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Clemens</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Hickling</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kenton</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Rondanina</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stapleton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stothers</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chai</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline.</article-title>
            <source>J Urol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>202</volume>
            <issue>2</issue>
            <fpage>282</fpage>
            <page-range>282-289</page-range>
            <pub-id pub-id-type="pmid">31042112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nace</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Drinka</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Crnich</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical uncertainties in the approach to long term care residents with possible urinary tract infection.</article-title>
            <source>J Am Med Dir Assoc</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-9</page-range>
            <pub-id pub-id-type="pmid">24461240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sundvall</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Ulleryd</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gunnarsson</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Urine culture doubtful in determining etiology of diffuse symptoms among elderly individuals: a cross-sectional study of 32 nursing homes.</article-title>
            <source>BMC Fam Pract</source>
            <year>2011</year>
            <month>May</month>
            <day>19</day>
            <volume>12</volume>
            <fpage>36</fpage>
            <pub-id pub-id-type="pmid">21592413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pouwels</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Llewelyn</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>McNulty</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Robotham</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Duration of antibiotic treatment for common infections in English primary care: cross sectional analysis and comparison with guidelines.</article-title>
            <source>BMJ</source>
            <year>2019</year>
            <month>Feb</month>
            <day>27</day>
            <volume>364</volume>
            <fpage>l440</fpage>
            <pub-id pub-id-type="pmid">30814052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kulchavenya</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Neymark</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Borisenko</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Kapsargin</surname>
                <given-names>FP</given-names>
              </name>
            </person-group>
            <article-title>[Acute uncomplicated cysititis: do we follow the guidelines?].</article-title>
            <source>Urologiia</source>
            <year>2018</year>
            <month>Dec</month>
            <issue>6</issue>
            <fpage>66</fpage>
            <page-range>66-69</page-range>
            <pub-id pub-id-type="pmid">30742380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phamnguyen</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hashem</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Single centre observational study on antibiotic prescribing adherence to clinical practice guidelines for treatment of uncomplicated urinary tract infection.</article-title>
            <source>Infect Dis Health</source>
            <year>2019</year>
            <month>May</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>75</fpage>
            <page-range>75-81</page-range>
            <pub-id pub-id-type="pmid">30598405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bono</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Reygaert</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Doerr</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <chapter-title>Uncomplicated Urinary Tract Infections (Nursing)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">33760460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bono</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Reygaert</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <chapter-title>Uncomplicated Urinary Tract Infections</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">29261874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swamy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kupelian</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Khasriya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dharmasena</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Toteva</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dehpour</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rohn</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Malone-Lee</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Cross-over data supporting long-term antibiotic treatment in patients with painful lower urinary tract symptoms, pyuria and negative urinalysis.</article-title>
            <source>Int Urogynecol J</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>409</fpage>
            <page-range>409-414</page-range>
            <pub-id pub-id-type="pmid">30564872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>May</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schostak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lebentrau</surname>
                <given-names>S</given-names>
              </name>
              <collab>MR2- study group</collab>
            </person-group>
            <article-title>Guidelines for patients with acute uncomplicated cystitis may not be a paper tiger: a call for its implementation in clinical routine.</article-title>
            <source>Int Urogynecol J</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>335</fpage>
            <page-range>335-336</page-range>
            <pub-id pub-id-type="pmid">30564871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bellazreg</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Abid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lasfar</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Hattab</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hachfi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Letaief</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic value of dipstick test in adult symptomatic urinary tract infections: results of a cross-sectional Tunisian study.</article-title>
            <source>Pan Afr Med J</source>
            <year>2019</year>
            <volume>33</volume>
            <fpage>131</fpage>
            <pub-id pub-id-type="pmid">31558930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Gaido</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Laboratory diagnosis of urinary tract infections in adult patients.</article-title>
            <source>Clin Infect Dis</source>
            <year>2004</year>
            <month>Apr</month>
            <day>15</day>
            <volume>38</volume>
            <issue>8</issue>
            <fpage>1150</fpage>
            <page-range>1150-8</page-range>
            <pub-id pub-id-type="pmid">15095222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Centor</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Humphrey</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Jokela</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Qaseem</surname>
                <given-names>A</given-names>
              </name>
              <collab>Scientific Medical Policy Committee of the American College of Physicians</collab>
              <name>
                <surname>Akl</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Bledsoe</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Forciea</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Haeme</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kansagara</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Marcucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Obley</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians.</article-title>
            <source>Ann Intern Med</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>174</volume>
            <issue>6</issue>
            <fpage>822</fpage>
            <page-range>822-827</page-range>
            <pub-id pub-id-type="pmid">33819054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKinnell</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Stollenwerk</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>LG</given-names>
              </name>
            </person-group>
            <article-title>Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>86</volume>
            <issue>6</issue>
            <fpage>480</fpage>
            <page-range>480-8</page-range>
            <pub-id pub-id-type="pmid">21576512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huttner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verhaegh</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Harbarth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Muller</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Theuretzbacher</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mouton</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>70</volume>
            <issue>9</issue>
            <fpage>2456</fpage>
            <page-range>2456-64</page-range>
            <pub-id pub-id-type="pmid">26066581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheele</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Libertin</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dasalla</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lyon</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>Alkaline Urine in the Emergency Department Predicts Nitrofurantoin Resistance.</article-title>
            <source>J Emerg Med</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>368</fpage>
            <page-range>368-377</page-range>
            <pub-id pub-id-type="pmid">35000812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iravani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Klimberg</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Briefer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Munera</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kowalsky</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Echols</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>43 Suppl A</volume>
            <fpage>67</fpage>
            <page-range>67-75</page-range>
            <pub-id pub-id-type="pmid">10225575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kavatha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Giamarellou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Alexiou</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Vlachogiannis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pentea</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gozadinos</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Poulakou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hatzipapas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koratzanis</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>897</fpage>
            <page-range>897-900</page-range>
            <pub-id pub-id-type="pmid">12604518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warren</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Abrutyn</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hebel</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Schaeffer</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Stamm</surname>
                <given-names>WE</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA).</article-title>
            <source>Clin Infect Dis</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>745</fpage>
            <page-range>745-58</page-range>
            <pub-id pub-id-type="pmid">10589881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicolle</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Thomson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Urias</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ronald</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of five years of continuous, low-dose trimethoprim-sulfamethoxazole prophylaxis for urinary tract infection.</article-title>
            <source>J Infect Dis</source>
            <year>1988</year>
            <month>Jun</month>
            <volume>157</volume>
            <issue>6</issue>
            <fpage>1239</fpage>
            <page-range>1239-42</page-range>
            <pub-id pub-id-type="pmid">3259613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stein</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection.</article-title>
            <source>Clin Ther</source>
            <year>1999</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>1864</fpage>
            <page-range>1864-72</page-range>
            <pub-id pub-id-type="pmid">10890258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falagas</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Vouloumanou</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Samonis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vardakas</surname>
                <given-names>KZ</given-names>
              </name>
            </person-group>
            <article-title>Fosfomycin.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>321</fpage>
            <page-range>321-47</page-range>
            <pub-id pub-id-type="pmid">26960938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schulz</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Sch&#x000fc;tz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Spielmann</surname>
                <given-names>FVJ</given-names>
              </name>
              <name>
                <surname>da Ros</surname>
                <given-names>LU</given-names>
              </name>
              <name>
                <surname>de Almeida</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>JGL</given-names>
              </name>
            </person-group>
            <article-title>Single-dose antibiotic therapy for urinary infections during pregnancy: A systematic review and meta-analysis of randomized clinical trials.</article-title>
            <source>Int J Gynaecol Obstet</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>159</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <page-range>56-64</page-range>
            <pub-id pub-id-type="pmid">34995367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatlen</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Flor</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>LG</given-names>
              </name>
            </person-group>
            <article-title>Oral fosfomycin use for pyelonephritis and complicated urinary tract infections: a 1 year review of outcomes and prescribing habits in a large municipal healthcare system.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2020</year>
            <month>Jul</month>
            <day>01</day>
            <volume>75</volume>
            <issue>7</issue>
            <fpage>1993</fpage>
            <page-range>1993-1997</page-range>
            <pub-id pub-id-type="pmid">32303061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wald-Dickler</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Tangpraphaphorn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Butler-Wu</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Degener</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Canamar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Holtom</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Spellberg</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Fosfomycin vs Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter, Retrospective Cohort Study.</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>ofab620</fpage>
            <pub-id pub-id-type="pmid">35036466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graninger</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Pivmecillinam--therapy of choice for lower urinary tract infection.</article-title>
            <source>Int J Antimicrob Agents</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>22 Suppl 2</volume>
            <fpage>73</fpage>
            <page-range>73-8</page-range>
            <pub-id pub-id-type="pmid">14527775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicolle</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Madsen</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Debeeck</surname>
                <given-names>GO</given-names>
              </name>
              <name>
                <surname>Blochlinger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Borrild</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bru</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Mckinnon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>O'Doherty</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Spiegel</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Van Balen</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Menday</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women.</article-title>
            <source>Scand J Infect Dis</source>
            <year>2002</year>
            <volume>34</volume>
            <issue>7</issue>
            <fpage>487</fpage>
            <page-range>487-92</page-range>
            <pub-id pub-id-type="pmid">12195873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nace</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Perera</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Hanlon</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Saracco</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schweon</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Klein-Fedyshin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wessel</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Mulligan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Drinka</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Crnich</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>The Improving Outcomes of UTI Management in Long-Term Care Project (IOU) Consensus Guidelines for the Diagnosis of Uncomplicated Cystitis in Nursing Home Residents.</article-title>
            <source>J Am Med Dir Assoc</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>765</fpage>
            <page-range>765-769.e3</page-range>
            <pub-id pub-id-type="pmid">30037743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cox</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bevins</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clemens</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Stoffel</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on intermittent catheterization.</article-title>
            <source>Can Urol Assoc J</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>9</issue>
            <fpage>E350</fpage>
            <page-range>E350-E354</page-range>
            <pub-id pub-id-type="pmid">29382457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r47">
          <label>47</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Lala</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Minter</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <chapter-title>Acute Cystitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">29083726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziadeh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chebel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Labaki</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Saliba</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Helou</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Bladder instillation for urinary tract infection prevention in neurogenic bladder patients practicing clean intermittent catheterization: A systematic review.</article-title>
            <source>Urologia</source>
            <year>2022</year>
            <month>May</month>
            <volume>89</volume>
            <issue>2</issue>
            <fpage>261</fpage>
            <page-range>261-267</page-range>
            <pub-id pub-id-type="pmid">34612750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lo</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Hammer</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Zegarra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>Methenamine: a forgotten drug for preventing recurrent urinary tract infection in a multidrug resistance era.</article-title>
            <source>Expert Rev Anti Infect Ther</source>
            <year>2014</year>
            <month>May</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>549</fpage>
            <page-range>549-54</page-range>
            <pub-id pub-id-type="pmid">24689705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kevorkian</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Merritt</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ilstrup</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Methenamine mandelate with acidification: an effective urinary antiseptic in patients with neurogenic bladder.</article-title>
            <source>Mayo Clin Proc</source>
            <year>1984</year>
            <month>Aug</month>
            <volume>59</volume>
            <issue>8</issue>
            <fpage>523</fpage>
            <page-range>523-9</page-range>
            <pub-id pub-id-type="pmid">6379319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kranj&#x0010d;ec</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pape&#x00161;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Altarac</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial.</article-title>
            <source>World J Urol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-84</page-range>
            <pub-id pub-id-type="pmid">23633128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kyriakides</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Somani</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Role of D-Mannose in the Prevention of Recurrent Urinary Tract Infections: Evidence from a Systematic Review of the Literature.</article-title>
            <source>Eur Urol Focus</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>1166</fpage>
            <page-range>1166-1169</page-range>
            <pub-id pub-id-type="pmid">32972899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenger</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bertolet</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Lowder</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Sutcliffe</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>223</volume>
            <issue>2</issue>
            <fpage>265.e1</fpage>
            <page-range>265.e1-265.e13</page-range>
            <pub-id pub-id-type="pmid">32497610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Nunzio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bartoletti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tubaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simonato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ficarra</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Role of D-Mannose in the Prevention of Recurrent Uncomplicated Cystitis: State of the Art and Future Perspectives.</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2021</year>
            <month>Apr</month>
            <day>01</day>
            <volume>10</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">33915821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grupper</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kravtsov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Potasman</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Emphysematous cystitis: illustrative case report and review of the literature.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>86</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-53</page-range>
            <pub-id pub-id-type="pmid">17220755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Remer</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Shoskes</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Emphysematous cystitis: a review of 135 cases.</article-title>
            <source>BJU Int</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>100</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-20</page-range>
            <pub-id pub-id-type="pmid">17506870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perry</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hossain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Raychaudhuri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scangarella-Oman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tiffany</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dumont</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Janmohamed</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants.</article-title>
            <source>Infect Dis Ther</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>2297</fpage>
            <page-range>2297-2310</page-range>
            <pub-id pub-id-type="pmid">36271314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fishman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caverly Rae</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Posobiec</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Laffan</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Lerman</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Janmohamed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dumont</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nunn-Floyd</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stanislaus</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Novel Bacterial Topoisomerase Inhibitor Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2022</year>
            <month>Nov</month>
            <day>15</day>
            <volume>66</volume>
            <issue>11</issue>
            <fpage>e0048322</fpage>
            <pub-id pub-id-type="pmid">36255258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiffany</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dumont</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Hossain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Swift</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics, safety, and tolerability of gepotidacin administered as single or repeat ascending doses, in healthy adults and elderly subjects.</article-title>
            <source>Clin Transl Sci</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>9</issue>
            <fpage>2251</fpage>
            <page-range>2251-2264</page-range>
            <pub-id pub-id-type="pmid">35769034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biedenbach</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Bouchillon</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Hackel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Scangarella-Oman</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Jakielaszek</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sahm</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2016</year>
            <month>Jan</month>
            <day>04</day>
            <volume>60</volume>
            <issue>3</issue>
            <fpage>1918</fpage>
            <page-range>1918-23</page-range>
            <pub-id pub-id-type="pmid">26729499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uehling</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Balish</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Heisey</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Vaginal mucosal immunization for recurrent urinary tract infection: phase II clinical trial.</article-title>
            <source>J Urol</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>157</volume>
            <issue>6</issue>
            <fpage>2049</fpage>
            <page-range>2049-52</page-range>
            <pub-id pub-id-type="pmid">9146577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uehling</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Elkahwaji</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Leverson</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections.</article-title>
            <source>J Urol</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>170</volume>
            <issue>3</issue>
            <fpage>867</fpage>
            <page-range>867-9</page-range>
            <pub-id pub-id-type="pmid">12913718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hopkins</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Elkahwaji</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Beierle</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Leverson</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Uehling</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial.</article-title>
            <source>J Urol</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>177</volume>
            <issue>4</issue>
            <fpage>1349</fpage>
            <page-range>1349-53; quiz 1591</page-range>
            <pub-id pub-id-type="pmid">17382730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eldridge</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Hughey</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rosenberger</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>D'Antonio</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Krejci</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Shore</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lukes</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Starks</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Safety and immunogenicity of an adjuvanted <italic>Escherichia coli</italic> adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: results from a first-in-human phase 1 study.</article-title>
            <source>Hum Vaccin Immunother</source>
            <year>2021</year>
            <month>May</month>
            <day>04</day>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>1262</fpage>
            <page-range>1262-1270</page-range>
            <pub-id pub-id-type="pmid">33325785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langermann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Palaszynski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barnhart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Auguste</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pinkner</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Burlein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barren</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Koenig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leath</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Hultgren</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination.</article-title>
            <source>Science</source>
            <year>1997</year>
            <month>Apr</month>
            <day>25</day>
            <volume>276</volume>
            <issue>5312</issue>
            <fpage>607</fpage>
            <page-range>607-11</page-range>
            <pub-id pub-id-type="pmid">9110982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forsyth</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Himpsl</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Sarkissian</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Mike</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Stocki</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sintsova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alteri</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Mobley</surname>
                <given-names>HLT</given-names>
              </name>
            </person-group>
            <article-title>Optimization of an Experimental Vaccine To Prevent Escherichia coli Urinary Tract Infection.</article-title>
            <source>mBio</source>
            <year>2020</year>
            <month>Apr</month>
            <day>28</day>
            <volume>11</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">32345645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beerepoot</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Geerlings</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>van Haarst</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>van Charante</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>ter Riet</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials.</article-title>
            <source>J Urol</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>190</volume>
            <issue>6</issue>
            <fpage>1981</fpage>
            <page-range>1981-9</page-range>
            <pub-id pub-id-type="pmid">23867306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20220.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Emphysematous pyelonephritis and cystitis in a patient with uremia and anuria: A case report and literature review.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>97</volume>
            <issue>45</issue>
            <fpage>e11272</fpage>
            <pub-id pub-id-type="pmid">30407278</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
